Medtronic Altaviva System
Medtronic Neuromodulation · Decision date Sep 18, 2025
What did the FDA approve?
FDA approved the Medtronic Altaviva System on September 18, 2025. The approval statement describes the device as indicated for treatment of urge urinary incontinence in patients who failed or could not tolerate more conservative treatments.
The database lists the product code QPT and device category as an implantable tibial electrical stimulator for urinary incontinence. The specialty field includes gastroenterology and urology. The statement does not include safety or effectiveness data, and the record does not identify this decision as a supplement.
FDA approval order statement
Approval for the Medtronic Altaviva System is indicated for treatment of urge urinary incontinence (UUI) in patients who failed or could not tolerate more conservative treatments.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Sep 18, 2025
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P240011
- Regulatory pathway
- Premarket approval application
- Applicant
- Medtronic Neuromodulation
- Product code
- QPT
- Decision code
- APPR
- Decision date
- Sep 18, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, tibial, electrical, implantable, for urinary incontinence.
- Applicant
- Medtronic Neuromodulation
- Product code
- QPT
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P240011 received
Application receipt date recorded by FDA.
P240011 · FDA decision
APPR
Timeline entries are records held by MedtechLedger for P240011. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240011
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
AltavivaP240011/S016 | Medtronic Neuromodulation | PMA supplement | Sep 14, 2026 | FDA |
Explore the linked device profile
Other records with product code QPT
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
eCoin Peripheral NeurostimulatorP200036/S012 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Sep 9, 2026 | FDA |
| BOSTON SCIENTIFIC CORPORATION | PMA approval | Mar 1, 2022 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Neuromodulation
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 7000 Central Ave. NE, Ms Rce480, Minneapolis, MN, 55432
Sources and methodology
- Original FDA record: P240011
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
